euro adhoc: LION Bioscience AG
Board of Directors (Appointments and Changes)
Management Board Change

---------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. ---------------------------------------------------------------------

Cambridge, MA, USA, Heidelberg, Germany, November 17, 2004 - The Supervisory Board of LION bioscience AG has reappointed LION´s Executive Board with immediate effect. Dr. Thure Etzold was appointed Chief Executive Officer (CEO). Peter Willinger, who is head of the finance department since 1998, was appointed Chief Financial Officer (CFO). Joseph F. Donahue moves from the Board and remains responsible for Global Sales and continues to be President of LION bioscience, Inc, LION’s U.S. subsidiary.

Peter Willinger joined LION in November 1998 as Director Controlling and served as Vice President Global Finance & Operations since October 2001. After he received his BA degree in business economics at the Mannheim University, he worked as a controller for Rudolf Wild GmbH & Co KG/Heidelberg for eight years.

end of announcement                                euro adhoc 17.11.2004 17:10:37

Further inquiry note: Günter Dielmann, Tel.: +49 6221 4038-249, Julia Fritz, Tel.: +49 6221 4038-158,

Branche: Pharmaceuticals
ISIN:      DE0005043509
WKN:        504350
Index:    Nemax 50, Prime Standard, TecDAX
Börsen:  Frankfurter Wertpapierbörse / regulated dealing
              New York / regulated dealing
              Berliner Wertpapierbörse / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Niedersächsische Börse zu Hannover / free trade
              Bayerische Börse / free trade
              Bremer Wertpapierbörse (BWB) / free trade

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: